Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort

Table 3 Cox models for drug retention of a second tumor necrosis factor inhibitor in patients having discontinued the first tumor necrosis factor inhibitor due to primary or secondary lack of response

	Patients with a clinical diagnosis of axSpA^a			Patients fulfilling the ASAS axSpA classification criteria^b
	HR	95 % CI	p Value	HR	95 % CI	p Value
SLR vs. PLR	0.56	0.42–0.75	<0.001	0.58	0.42–0.81	0.002
Female vs. male	0.94	0.71–1.24	0.65	0.90	0.64–1.25	0.53
Age	1.00	0.99–1.02	0.73	1.00	0.99–1.02	0.93
Cept → mAb^c	1.11	0.79–1.55	0.56	1.17	0.78–1.73	0.45
mAb → Cept^c	1.11	0.80–1.56	0.54	1.24	0.84–1.82	0.28
2007–2010 vs. before 2006	1.26	0.50–3.12	0.63	1.18	0.47–2.96	0.73
2010–2015 vs. before 2006	1.58	0.63–3.99	0.33	1.44	0.57–3.67	0.44

ASAS Assessment of SpondyloArthritis international Society, axSpA axial spondyloarthritis, Cept soluble receptor anti–tumor necrosis factor agent, mAb monoclonal antibody anti–tumor necrosis factor agent, HR hazard ratio, CI confidence Interval, PLR primary lack of response, SLR secondary lack of response
^aTotal of 416 patients and 207 discontinuation events
^bTotal of 330 patients and 157 discontinuation events
^cIndicated switch type versus reference category mAb → mAb

ISSN: 1478-6362